• A phase 3 trial examining Novo Nordisk's (NVO) GLP-1 medicine semaglutide as a treatment for metabolic dysfunction-associated steatohepatitis (MASH) met its primary endpoints.
• Those endpoints were significant improvement in liver fibrosis with no worsening of steatohepatitis, and no worsening of liver fibrosis in those with MASH compared to placebo.
• In the study, 2.4 mg semaglutide was given subcutaneously once a week.
• Results from part 1 of the ESSENCE trial showed that at week 72, 62.9% of people treated with semaglutide achieved resolution of steatohepatitis with no worsening of liver fibrosis compared to 34.1% on placebo. Also, 37% of people treated with semaglutide 2.4 mg achieved improvements in liver fibrosis with no worsening of steatohepatitis compared to 22.5% on placebo.
• A secondary endpoint found 32.8% of those on semaglutide 2.4 mg achieved both resolution of steatohepatitis with improvements in liver fibrosis vs. 16.2% of placebo patients.
• Semaglutide is also sold by Novo as a type 2 diabetes medicine under the name Ozempic and as a weight loss treatment called Wegovy.

免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。